2. Cell Cycle/DNA Damage Apoptosis Anti-infection Metabolic Enzyme/Protease NF-κB Immunology/Inflammation
  3. Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS)
  4. Ciprofloxacin monohydrochloride

Ciprofloxacin monohydrochloride  (Synonyms: Bay-09867 monohydrochloride)

Cat. No.: HY-B0356A Purity: 99.90%
COA
SDS
Handling Instructions Technical Support

Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

For research use only. We do not sell to patients.

CAS No. : 93107-08-5

Size Price Stock Quantity
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 52 publication(s) in Google Scholar

Other Forms of Ciprofloxacin monohydrochloride:

Ciprofloxacin monohydrochloride Related Antibodies

Top Publications Citing Use of Products

52 Publications Citing Use of MCE Ciprofloxacin monohydrochloride

Bio/Physico-chemical Assay
Microbiological Assay
Others
2D/3D Cell Culture and Differentiation
Flow Cytometry

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

    The number of surviving bacteria after 24 h of treatment with free Ciprofloxacin monohydrochloride or Ciprofloxacin monohydrochloride-loaded liposomes at 658 a 3 μg/mL of Ciprofloxacin monohydrochloride concentration.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Chem Eng J. 2025 May 1.

    The CI values for 660 antibacterial efficacy of blank liposomes and Ciprofloxacin monohydrochloride.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885.  [Abstract]

    Ciprofloxacin (CIP, 3 or 8 μg/L, 0-7 days) caused concentration-dependent damage in M. aeruginosa cells.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885.  [Abstract]

    Ciprofloxacin (CIP, 3 or 8 μg/L, 3 or 7 days) increased the release and decreased the biosynthesis of MC-LR in M. aeruginosa cells.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885.  [Abstract]

    Ciprofloxacin (CIP, 8 μg/L, 1 day) enriched gene ontology terms related to PSI in M. aeruginosa cells.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885.  [Abstract]

    Ciprofloxacin (CIP, 3 or 8 μg/L, 21 days) induced continuous cell lysis, with maximum lytic rates of ∼70% compared to the initial cell density.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: Water Res. 2024 Nov 29:271:122885.  [Abstract]

    Ciprofloxacin (CIP, 3 or 8 μg/L, 1, 3, 5, or 7 days) induced cell death in M. aeruginosa.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

    Representative TEM images of blank micelles (BM) and Ciprofloxacin monohydrochloride-loaded micelles (CM) formulated in 1× PBS at pH 7.4.

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

    Cumulative ciprofloxacin release from Ciprofloxacin monohydrochloride-loaded micelles over 72 h with an inset of the release over the first 12 h at pH 4.4 (red) and pH 7.4 (gray).

    Ciprofloxacin monohydrochloride purchased from MedChemExpress. Usage Cited in: ACS Appl Polym Mater. 2023 Aug 29.

    Cumulative Ciprofloxacin monohydrochloride release at 12 and 72 h.

    View All Topoisomerase Isoform Specific Products:

    View All Isoforms
    Topoisomerase Topo I Topo II DNA gyrase

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].

    IC50 & Target

    Quinolone

     

    Cellular Effect
    Cell Line Type Value Description References
    L6 IC50
    3.3998 μM
    Compound: Ciprofloxacin Hydrochloride
    Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
    Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
    		[PMID: 32623216]
    In Vitro

    Ciprofloxacin (Bay-09867) monohydrochloride (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase[1].
    Ciprofloxacin (Bay-09867) monohydrochloride shows potent activity against Y. pestis and B. anthracis with MIC90 of 0.03 μg/mL and 0.12 μg/mL, respectively[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ciprofloxacin monohydrochloride Related Antibodies

    Cell Viability Assay[1]

    Cell Line: Tendon cells
    Concentration: 5, 10, 20 and 50 μg/mL
    Incubation Time: 24 hours
    Result: Decreased the cellularity of tendon cells.

    Cell Cycle Analysis[1]

    Cell Line: Tendon cells
    Concentration: 50 μg/mL
    Incubation Time: 24 hours
    Result: Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.

    Western Blot Analysis[1]

    Cell Line: Tendon cells
    Concentration: 50 μg/mL
    Incubation Time: 0, 6, 12, 17 and 24 hours
    Result: Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.
    In Vivo

    Ciprofloxacin (Bay-09867) monohydrochloride (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague[3].
    Ciprofloxacin (Bay-09867) monohydrochloride (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall[4].
    Ciprofloxacin (Bay-09867) monohydrochloride (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: BALB/c mice[3]
    Dosage: 30 mg/kg
    Administration: Intraperitoneal injection; for 24 hours
    Result: Reduced the lung bacterial load in murine model of pneumonic plague.
    Animal Model: C57BL/6J mice[4]
    Dosage: 100 mg/kg
    Administration: Oral gavage; daily, for 4 weeks
    Result: Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.
    Animal Model: C57BL/6J mice[4]
    Dosage: 100 mg/kg
    Administration: Oral gavage; daily, for 4 weeks
    Result: Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.
    Clinical Trial
    Molecular Weight

    367.81

    Formula

    C17H19ClFN3O3
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    [H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    4°C, sealed storage, away from moisture and light

    *The compound is unstable in solutions, freshly prepared is recommended.

    Solvent & Solubility
    In Vitro: 

    H2O : 12.5 mg/mL (33.99 mM; Need ultrasonic)

    DMSO : 5 mg/mL (13.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.7188 mL 13.5940 mL 27.1881 mL
    5 mM 0.5438 mL 2.7188 mL 5.4376 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

      This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *The compound is unstable in solutions, freshly prepared is recommended.

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 100%

    SDS (393 KB)

    COA (249 KB) HNMR (230 KB) LCMS (93 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO / H2O 1 mM 2.7188 mL 13.5940 mL 27.1881 mL 67.9702 mL
    5 mM 0.5438 mL 2.7188 mL 5.4376 mL 13.5940 mL
    10 mM 0.2719 mL 1.3594 mL 2.7188 mL 6.7970 mL
    H2O 15 mM 0.1813 mL 0.9063 mL 1.8125 mL 4.5313 mL
    20 mM 0.1359 mL 0.6797 mL 1.3594 mL 3.3985 mL
    25 mM 0.1088 mL 0.5438 mL 1.0875 mL 2.7188 mL
    30 mM 0.0906 mL 0.4531 mL 0.9063 mL 2.2657 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ciprofloxacin monohydrochloride Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ciprofloxacin monohydrochloride93107-08-5Bay-09867 monohydrochlorideTopoisomeraseApoptosisAntibioticBacterialMitochondrial MetabolismReactive Oxygen Species (ROS)mitochondrialDNADNA damageanti-proliferativeantibioticROSInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ciprofloxacin monohydrochloride
    Cat. No.:
    HY-B0356A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.